Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.035,69
-1,57%
NASDAQ Composite
15.657,82
-2,04%
Bitcoin
57.515,19
-5,09%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Agenus Inc (AGEN) Agenus Inc (AGEN) Notizie

AGEN

Agenus (AGEN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AGEN
DataOraFonteTitoloSimboloCompagnia
24/04/202416:00Business WireBotensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual MeetingNASDAQ:AGENAgenus Inc
23/04/202413:30Business WireAgenus to Provide First Quarter 2024 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
12/04/202413:30Business WireAgenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal CancerNASDAQ:AGENAgenus Inc
05/04/202422:30Business WireAgenus Announces Reverse Stock Split of Common StockNASDAQ:AGENAgenus Inc
14/03/202412:30Business WireAgenus Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:AGENAgenus Inc
06/03/202413:30Business WireAgenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024NASDAQ:AGENAgenus Inc
05/03/202422:30Business WireAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AGENAgenus Inc
29/02/202422:50Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AGENAgenus Inc
29/02/202413:30Business WireAgenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial ReportNASDAQ:AGENAgenus Inc
26/02/202422:24Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AGENAgenus Inc
26/02/202413:30Business WireAgenus to Participate in Leerink Partners Global Biopharma ConferenceNASDAQ:AGENAgenus Inc
15/02/202414:02Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AGENAgenus Inc
15/02/202414:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
15/02/202413:02PR Newswire (US)Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular DesignNASDAQ:AGENAgenus Inc
14/02/202414:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AGENAgenus Inc
12/02/202413:00Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
31/01/202413:30Business WireAgenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:AGENAgenus Inc
22/01/202415:59Business WireBotensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer PopulationNASDAQ:AGENAgenus Inc
04/01/202413:30Business WireAgenus to Participate in B. Riley Healthcare ConferenceNASDAQ:AGENAgenus Inc
04/01/202412:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
20/12/202313:30Business WireBotensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024NASDAQ:AGENAgenus Inc
11/12/202313:30Business WireAgenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific ProgramNASDAQ:AGENAgenus Inc
09/11/202322:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGENAgenus Inc
07/11/202312:30Business WireAgenus Reports Third Quarter 2023 ResultsNASDAQ:AGENAgenus Inc
26/10/202315:05Business WireAgenus to Provide Third Quarter 2023 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
22/10/202318:00Business WireAgenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and SarcomaNASDAQ:AGENAgenus Inc
21/10/202310:15Business WireESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma SubtypesNASDAQ:AGENAgenus Inc
10/10/202313:30Business WireAgenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal CancerNASDAQ:AGENAgenus Inc
05/10/202313:30Business WireAgenus To Host BOT/BAL Program Update at ESMO 2023NASDAQ:AGENAgenus Inc
28/08/202313:30Business WireAgenus to Participate in September Investor ConferencesNASDAQ:AGENAgenus Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AGEN

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
TEN
Tenaris
BIT
TIT
Telecom Italia
BIT
LDO
Leonardo
BIT
SPM
Saipem
BIT
SRG
Snam
BIT
FBK
Finecobank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network